|Year : 2018 | Volume
| Issue : 4 | Page : 469-472
Correlation between basal insulin glargine dose required in achieving target fasting blood glucose and various clinical and laboratory parameters in hospitalized noncritical patients
Om J Lakhani, Surender Kumar, Sudhir Tripathi, Mitali A Desai, Chandani Seth
Department of Endocrinology and Metabolism, Sir Ganga Ram Hospital, New Delhi, India
|Date of Web Publication||31-Jul-2018|
Om J Lakhani
Department of Endocrinology, Sir Ganga Ram Hospital, New Delhi
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Aims: The primary objective was to study the interrelationship between the basal insulin glargine dose and baseline clinical and laboratory parameters in noncritically ill hospitalized patients who have achieved the stable fasting blood glucose in the target range of 100–140 mg/dl. Patients and Methods: This was retrospective, cross-sectional, observational study. Consenting, nonpregnant, adult patients on basal-bolus insulin who had fasting capillary blood glucose in the range of 100–140 mg/dl as measured by glucometer for 3 consecutive days were included in this study. Patient receiving any basal insulin other than insulin glargine were excluded from this study. The data collected for these patients included age, sex, glycated hemoglobin (HBA1c) at the time of admission, timing of basal insulin, basal insulin dose (BID), BID/kg, weight, and serum creatinine. BID/kg was correlated with other parameters using regression analysis (Pearson's). Comparison of BID/kg in various subgroups was analyzed using Student's t- test. Parametric data of more than three groups were compared using ANOVA. The P < 0.05 was considered as statistically significant. Results: A total of 180 patients were included in the study. On correlating the BID/kg with various parameters, we found statistically significant correlation between BID/kg and glycated hemoglobin (HbA1c) at the time of admission (P = 0.044). Patients with HbA1c ≥8.0% had higher BID/kg compared to those with HbA1c <8.0% (P = 0.004). The mean BID in patients with renal failure was significantly higher compared to those without renal failure. Conclusion: HbA1c at the time of admission is the most important parameter for determining the appropriate BID in hospitalized patients. Patients with renal failure may require a higher dose of basal insulin than those not having renal failure.
Keywords: Basal insulin, glargine, hospital hyperglycemia, in-hospital hyperglycemia
|How to cite this article:|
Lakhani OJ, Kumar S, Tripathi S, Desai MA, Seth C. Correlation between basal insulin glargine dose required in achieving target fasting blood glucose and various clinical and laboratory parameters in hospitalized noncritical patients. Indian J Endocr Metab 2018;22:469-72
|How to cite this URL:|
Lakhani OJ, Kumar S, Tripathi S, Desai MA, Seth C. Correlation between basal insulin glargine dose required in achieving target fasting blood glucose and various clinical and laboratory parameters in hospitalized noncritical patients. Indian J Endocr Metab [serial online] 2018 [cited 2019 Mar 24];22:469-72. Available from: http://www.ijem.in/text.asp?2018/22/4/469/238115
| Introduction|| |
Management of hyperglycemia in hospitalized patients needs to be done effectively and quickly to achieve euglycemia. The Endocrine Society Guidelines recommend the use of basal-bolus insulin in the management of hyperglycemia in hospitalized patients. The guidelines recommend that starting dose insulin as 0.2–0.5 units/kg, of which 50% is basal insulin which makes the starting dose of basal insulin as 0.1–0.25 units/kg. This recommendation comes from the RABBIT-2 trial. The trial used insulin glargine as the choice of basal insulin. If the fasting blood glucose was >140 mg/dl, then the basal insulin glargine dose was increased by 20% everyday to achieve a target range of 70–140 mg/dl in the aforementioned trial.
It is often noticed in clinical practice that the starting dose of basal insulin as recommended by the guidelines is often inadequate. In various trials done for the use of basal insulin in outpatient department (OPD), the basal insulin dose (BID) requirement has been anywhere from 23 units/day to as much as 80 units/day to reach a target fasting blood glucose <130 mg/dl from a baseline value of an average of 200 mg/dl. It is, hence, obvious that a starting dose of 0.2 units/kg of basal insulin would surely be inadequate to achieve a desired glycemic control in patients who typically present in the hospital with high fasting plasma glucose values. In addition, while in OPD patients, the clinician has the luxury of gradual titration of the insulin dose, and in hospitalized patients, there is often a sense of urgency to achieve a good glycemic control as early as possible. In such a scenario, the prescribed BID by Endocrine Society may prove inadequate.
The primary objective was to study the interrelationship between the basal insulin glargine dose (in units/kg) and baseline clinical and laboratory parameters in noncritically ill hospitalized patients who have achieved the stable fasting blood glucose in the target range of 100–140 mg/dl.
| Patients and Methods|| |
This was a retrospective, cross-sectional, observational study. This study was conducted at a single tertiary care institution in New Delhi. Permission for the study was granted by the institutional ethics committee. This study was conducted from January 2015 to August 2015.
Nonpregnant, adult, and diabetic patients admitted to noncritical beds in the hospital and treated with basal-bolus insulin regime were screened for eligibility for inclusion in the study. The BID was titrated in all patients as described in the protocol of the RABBIT-2 trial, and the Endocrine Society Guidelines to achieve a fasting capillary blood glucose in the target range of 100–140 mg/dl.,
Patients who achieved stable fasting capillary blood glucose in the target range of 100–140 mg/dl as measured by glucometer for 3 consecutive days were included in the study. Written consent was taken from the patients who were eligible for inclusion in the study.
Patient receiving any basal insulin other than insulin glargine were excluded from the study. Patients who refused to give consent, those taking oral antidiabetics during the hospital stay or those who were on glucocorticoids were excluded from the study.
The data collected for these patients included age, gender, glycated hemoglobin (HBA1c) at the time of admission, timing of basal insulin, BID, BID/kg, weight, and serum creatinine. The data for the BID and BID/kg were taken during the period of stable fasting plasma blood glucose in the range of 100–140 mg/dl.
Clinical and laboratory methods
Body mass index (BMI) was calculated from weight (in kg) and height (in m) of the patients as weight/height. Estimated glomerular filtration rate (eGFR) was calculated from the MDRD study equation.
Contour® Next glucometer was used for capillary blood glucose measurements (manufactured by Bayer HealthCare LLC). Fingertips were used for capillary blood glucose sample using standard lancing device provided by the manufacturer. The test strips used flavin adenine dinucleotide-glucose dehydrogenase method for blood glucose testing. The results of the glucometer are referenced to plasma/serum blood glucose values. The measuring range of the glucometer is 10–600 mg/dl.
Plasma glucose concentration was measured with glucose oxidase method on Beckman Coulter Unicel DXC-800 analyzer. HbA1c was measured using ion-exchange high-performance liquid chromatography (Bio-Rad D-10 analyzer). The reference range of the test was from 3.8% to 18.5%.
BID/kg was correlated with other parameters using regression analysis (Pearson's). Comparison of BID/kg in various subgroups was analyzed using Student's t-test. Multivariate regression analysis was performed with BID/kg as the dependent variable to analyze the individual contributions of age, gender, BMI, HbA1c, and eGFR.
Parametric data of more than three groups was compared using ANOVA. The P > 0.05 was considered as statistically significant.
Parametric data were reported as mean ± standard deviation, and nonparametric data were reported as median (with interquartile range). SPSS version 20 (IBM, Chicago, IL, USA) was used for carrying out statistical analysis.
| Results|| |
A total of 180 patients were included in this study. The baseline data of the patients are shown in [Table 1]. The mean BID was 25 ± 12 units, and the mean BID/kg was 0.33 ± 0.14 units/kg.
On correlating the BID/kg with various parameters, we found statistically significant correlation between BID/kg and HbA1c at the time of admission (P = 0.044). No significant correlation was found with age, BMI, and eGFR.
Patients with HbA1c ≥8.0% had higher BID/kg (0.44 ± 0.08 units/kg) compared to those with HbA1c <8.0% (0.28 ± 0.11 units/kg) (P = 0.004) [Figure 1]. There was no statistically significant difference in BID/kg in patients with HbA1c <6.5% when compared to those with HbA1c between 6.5% and 8.0% (P = 0.65).
|Figure 1: Basal insulin dose/kg in two groups based on glycated hemoglobin|
Click here to view
We compared the mean BID/kg in patients with renal failure (defined as eGFR <60 ml/min/1.73 m 2) with those not having renal failure. The mean BID in patients with renal failure was higher (0.42 ± 0.15 units/kg) than those without renal failure (0.3 ± 0.12 units/kg). The difference between the two groups was statistically significant (P = 0.013) [Figure 2].
There was no significant difference in the BID among elderly patients (defined as those having age ≥70 kg) versus nonelderly (P = 0.84). The time of the basal insulin administration (morning vs. afternoon vs. evening) did not influence the BID (P = 0.47). There was no significant difference in the BID/kg in men versus women (P = 0.42).
Multivariate analysis revealed significant and independent correlation between BID/kg and HbA1c (P = 0.04) and eGFR (P = 0.014). The correlation coefficient between eGFR and the BID/kg was negative; meaning the patients with lower eGFR required a higher BID.
| Discussion|| |
The recommendation of Endocrine Society for starting BID is shown in [Table 2]. Some of the results from our study show that the starting BID as recommended by these guidelines may be much lower than what we have seen in our study. The mean BID in the RABBIT-2 trial was 22 ± 2 units, whereas the mean BID in this study was 25 ± 12 units.
|Table 2: Recommended starting dose of basal insulin dose (Adapted from Endocrine society guidelines for In-hospital hyperglycemia|
Click here to view
Papa et al. performed a study to find correlation between various anthropometric, clinical and laboratory parameters, and the BID. Patients on oral antidiabetic agents were also included in the abovementioned study. Papa et al. found a difference in the BID between male and female, whereas we found no difference with regards to gender. They also found a correlation between HbA1c and the BID. There was no correlation between age and BID in their study.
The higher basal insulin requirement in patients with high HbA1c in this study can be ascribed to glucotoxicity and lipotoxicity caused by long-standing uncontrolled diabetes. Glucotoxicity and oxidative stress, which are associated with long-standing uncontrolled diabetes, are well known to worsen insulin resistance.
Clinicians often tend to start a lower dose of basal insulin in patients with renal failure. Indeed, the Endocrine Society Guidelines recommend lower starting dose of insulin in patients with renal failure. However, we found in our study that patients with renal failure actually required a higher insulin dose compared to those not having renal failure. Insulin resistance is known to be high in patients with renal failure which can explain the phenomenon that we observed. A study performed in Australia observed patients with higher grades of chronic kidney disease (CKD) have reduced physical activity which can lead to increased insulin resistance. Vitamin D is known to reduce insulin resistance. Patients with advanced CKD have reduced 1,25 dihydroxyvitamin D, especially when the glomerular filtration rate (GFR) is <30 mL/min/1.73 m 2. Hence, reduced 1,25 dihydroxyvitamin D possibly explains the increased insulin resistance seen in advanced CKD. Another explanation is the secondary hyperparathyroidism due to deficiency of vitamin D and phosphate retention in CKD may be the etiology for the increased insulin resistance. It has also been proposed that metabolic acidosis seen in patients with advanced CKD, may be responsible for the enhanced insulin resistance. Inflammation and oxidative stress are higher in CKD and may have link with insulin resistance.
The results from our study can prove to be extremely useful to a practicing endocrinologist. HbA1c should be an important determinant while analyzing the BID in hospitalized diabetic patients. We recommend additional research to understand the insulin dosing requirement in patients with renal failure.
Our study is limited by a small patient number. In addition, the study is retrospective in nature, and a prospective study on similar lines may prove very useful in understanding the appropriate BID requirement. The study of other potential parameters such as waist circumference and the presence/absence of diabetic microvascular and macrovascular complications would have given us further insights into the factors affecting the BID requirement.
| Conclusion|| |
HbA1c at the time of admission is the most important parameter for determining the appropriate BID in hospitalized patients. Patients with HbA1c >8.0% have a higher mean basal insulin requirement than those with HBA1c <8.0. Patients with renal failure (GFR <60 ml/min/1.73 m 2) may require a higher dose of basal insulin than those not having renal failure. Age, gender, BMI, and timing of basal insulin have little impact on the BID.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al.
Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16-38.
Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al.
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-6.
Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007;1:540-8.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al.
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
Klaff LJ, Brazg R, Hughes K, Tideman AM, Schachner HC, Stenger P, et al.
Accuracy evaluation of contour next compared with five blood glucose monitoring systems across a wide range of blood glucose concentrations occurring in a clinical research setting. Diabetes Technol Ther 2015;17:8-15.
Papa G, Baratta R, Calì V, Degano C, Iurato MP, Licciardello C, et al.
Factors that influence basal insulin requirement in type 2 diabetes. Acta Diabetol 2012;49:387-93.
Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress. World J Gastroenterol 2009;15:4137-42.
Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: A systematic review. Am J Physiol Renal Physiol 2016;311:F1087-108.
Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM. The effect of improved serum 25-hydroxyvitamin D status on glycemic control in diabetic patients: A Meta-analysis. J Clin Endocrinol Metab 2017;102:3097-110.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al.
Prevalence of abnormal serum Vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
[Figure 1], [Figure 2]
[Table 1], [Table 2]